Innohep (Tinzaparin Sodium)

Tinzaparin sodium enhances the activity of antithrombin III, which selectively inhibits factor Xa and, to a lesser extent, thrombin (factor IIa). By blocking these key enzymes in the coagulation cascade, the drug reduces thrombin generation and fibrin clot formation while preserving some normal hemostasis.

The dose of Innohep is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and risk factors. Healthcare professionals determine the appropriate dosing regimen and administration schedule for each patient.

Data on the use of tinzaparin during pregnancy and lactation are limited. Innohep should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and its use should be guided by a qualified healthcare provider.

To order Innohep, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Innohep, as a low molecular weight heparin, offers more predictable pharmacokinetics and does not require routine laboratory monitoring compared with unfractionated heparin. Compared with direct oral anticoagulants, it is administered by injection and may be preferred in patients with severe renal impairment or when rapid reversal is needed.

Innohep should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any solution that appears discolored or contains particles.

Innohep is given by subcutaneous injection, typically into the abdominal wall or thigh. The injection site should be rotated with each dose, and aseptic technique must be used. In some clinical settings, intravenous administration may be employed under strict medical supervision.

The most serious risks include major bleeding events such as intracranial or gastrointestinal hemorrhage, heparin‑induced thrombocytopenia (HIT), and rare but severe allergic reactions. Patients should be monitored for signs of bleeding, sudden platelet count drops, or hypersensitivity during therapy.

Innohep is contraindicated in patients with known hypersensitivity to tinzaparin or any heparin product, those with active major bleeding, and individuals with a history of heparin‑induced thrombocytopenia. Caution is also advised for patients with severe renal impairment, uncontrolled hypertension, or recent spinal/epidural procedures.